Publications for Michael Boyer
Publications for Michael Boyer
2016
Ramalingam, S., O'Byrne, K., Boyer, M., Mok,
T., Janne, P., Zhang, H., Liang, J., Taylor, I.,
Sbar, E., Paz-Ares, L. (2016). Dacomitinib
versus erlotinib in patients with EGFR-mutated
advanced nonsmall-cell lung cancer (NSCLC):
pooled subset analyses from two randomized
trials. Annals of Oncology, 27(3), 423-429. <a
href="http://dx.doi.org/10.1093/annonc/mdv593"
>[More Information]</a>
Luk, P., Weston, J., Yu, B., Selinger, C.,
Ekmejian, R., Eviston, T., Lum, T., Gao, K.,
Boyer, M., O'Toole, S., Clark, J., Gupta, R.
(2016). Salivary duct carcinoma:
Clinicopathologic features, morphologic
spectrum, and somatic mutations. Head and
Neck, 38(Suppl 1), e1838-e1847. <a
href="http://dx.doi.org/10.1002/hed.24332">[Mo
re Information]</a>
2015
Davidson, A., Veillard, A., Tognela, A., Chan,
M., Huighes, B., Boyer, M., Briscoe, K., Begbie,
S., Abdi, E., Crombie, C., Chinchen, S.,
Espinoza, D., Coskinas, X., Pavlakis, N.,
Stockler, M., et al (2015). A phase III
randomized trial of adding topical nitroglycerin
to first-line chemotherapy for advanced
nonsmall-cell lung cancer: the Australasian lung
cancer trials group NITRO trial. Annals of
Oncology, 26(11), 2280-2286. <a
href="http://dx.doi.org/10.1093/annonc/mdv373"
>[More Information]</a>
Kao, S., Fulham, M., Wong, K., Cooper, W.,
Brahmbhatt, H., MacDiarmid, J., Pattison, S.,
Sagong, J., Huynh, Y., Leslie, F., Pavlakis, N.,
Clarke, S., Boyer, M., Reid, G., van Zandwijk,
N. (2015). A significant metabolic and
radiological response after a novel targeted
microRNA-based treatment approach in
malignant pleural mesothelioma. American
Journal of Respiratory and Critical Care
Medicine, 191(12), 1467-1469. <a
href="http://dx.doi.org/10.1164/rccm.201503-04
61LE">[More Information]</a>
Yang, J., Wu, Y., Schuler, M., Sebastian, M.,
Popat, S., Yamamoto, N., Zhou, C., Hu, C.,
O'Byrne, K., Feng, J., Boyer, M., et al (2015).
Afatinib versus cisplatin-based chemotherapy for
EGFR mutation-positive lung adenocarcinoma
(LUX-Lung 3 and LUX-Lung 6): analysis of
overall survival data from two randomised, phase
3 trials. Lancet Oncology, 16(2), 141-151. <a
href="http://dx.doi.org/10.1016/S1470-2045(14)
71173-8">[More Information]</a>
Mahon, K., Lin, H., Castillo, L., Lee, B.,
Lee-Ng, K., Chatfield, M., Chiam, K., Breit, S.,
Brown, D., Molloy, M., Marx, G., Pavlakis, N.,
Boyer, M., Stockler, M., Horvath, L., et al
(2015). Cytokine profiling of docetaxel-resistant
castration-resistant prostate cancer. British
Journal of Cancer, 112(8), 1340-1348. <a
href="http://dx.doi.org/10.1038/bjc.2015.74">[M
ore Information]</a>
Cooper, W., Tran, T., Vilain, R., Madore, J.,
Selinger, C., Kohonen-Corish, M., Yip, P., Yu,
B., O'Toole, S., McCaughan, B., Horvath, L.,
Kao, S., Boyer, M., Scolyer, R., et al (2015).
PD-L1 expression is a favorable prognostic
factor in early stage non-small cell carcinoma.
Lung Cancer, 89(2), 181-188. <a
href="http://dx.doi.org/10.1016/j.lungcan.2015.0
5.007">[More Information]</a>
2014
Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee,
B., Nguyen, Q., Boyer, M., Stockler, M.,
Pavlakis, N., Marx, G., Gurney, H., Horvath, L.,
et al (2014). Circulating microRNAs are
associated with docetaxel chemotherapy outcome
in castration-resistant prostate cancer. British
Journal of Cancer, 110(10), 2462-2471. <a
href="http://dx.doi.org/10.1038/bjc.2014.181">[
More Information]</a>
Tattersall, M., Martin, A., Devine, R., Ryan, J.,
Jansen, J., Hastings, L., Boyer, M., Glare, P.,
Stockler, M., Butow, P. (2014). Early Contact
with Palliative Care Services: A Randomized
Trial in Patients with Newly Detected Incurable
Metastatic Cancer. Journal of Palliative Care &
Medicine, 4(1), 1-6. <a
href="http://dx.doi.org/10.4172/2165-7386.1000
170">[More Information]</a>
Mahon, K., Qu, W., Devaney, J., Paul, C.,
Castillo, L., Wykes, R., Chatfield, M., Boyer,
M., Stockler, M., Marx, G., Gurney, H., Horvath,
L., et al (2014). Methylated Glutathione
S-transferase 1 (mGSTP1) is a potential plasma
free DNA epigenetic marker of prognosis and
response to chemotherapy in castrate-resistant
prostate cancer. British Journal of Cancer,
111(9), 1802-1809. <a
href="http://dx.doi.org/10.1038/bjc.2014.463">[
More Information]</a>
Yip, P., Cooper, W., Kohonen-Corish, M., Lin,
B., McCaughan, B., Boyer, M., Kench, J.,
Horvath, L. (2014). Phosphorylated Akt
expression is a prognostic marker in early-stage
non-small cell lung cancer. Journal of Clinical
Pathology, 67(4), 333-340. <a
href="http://dx.doi.org/10.1136/jclinpath-2013-2
01870">[More Information]</a>
Laurie, S., Solomon, B., Seymour, L., Ellis, P.,
Goss, G., Shepherd, F., Boyer, M., Arnold, A.,
Clingan, P., Laberge, F., Stockler, M., et al
(2014). Randomised, double-blind trial of
Publications for Michael Boyer
carboplatin and paclitaxel with daily oral
cediranib or placebo in patients with advanced
non-small cell lung cancer: NCIC Clinical Trials
Group study BR29. European Journal of Cancer,
50(4), 706-712. <a
href="http://dx.doi.org/10.1016/j.ejca.2013.11.03
2">[More Information]</a>
Charakidis, M., Boyer, M. (2014). Targeting
MET and EGFR in NSCLC-what can we learn
from the recently reported phase III trial of
onartuzumab in combination with erlotinib in
advanced non-small cell lung cancer?
Translational Lung Cancer Research, 3(6),
395-396. <a
href="http://dx.doi.org/10.3978/j.issn.2218-6751.
2014.09.03">[More Information]</a>
2013
McCaughan, G., Blinman, P., Boyer, M.,
Stockler, M. (2013). Better estimates of survival
for patients considering adjuvant chemotherapy
after surgery for early non-small-cell lung
cancer. Internal Medicine Journal, 43(4),
424-429. <a
href="http://dx.doi.org/10.1111/j.1445-5994.201
2.02846.x">[More Information]</a>
van Zandwijk, N., Clarke, C., Henderson, D.,
Musk, A., Fong, K., Nowak, A., Loneragan, R.,
McCaughan, B., Boyer, M., Feigen, M., et al
(2013). Guidelines for the diagnosis and
treatment of malignant pleural mesothelioma.
Journal of Thoracic Disease, 5(6), E254-E307.
<a
href="http://dx.doi.org/10.3978/j.issn.2072-1439.
2013.11.28">[More Information]</a>
Spina, R., Chu, S., Chatfield, M., Chen, J., Tin,
M., Boyer, M. (2013). Outcomes of
Chemoradiation for Patients with Locally
Advanced Non-Small-Cell Lung Cancer.
Internal Medicine Journal, 43(7), 790-797. <a
href="http://dx.doi.org/10.1111/imj.12138">[Mo
re Information]</a>
Yip, P., Yu, B., Cooper, W., Selinger, C., Ng, C.,
Kennedy, C., Kohonen-Corish, M., McCaughan,
B., Trent, R., Boyer, M., Kench, J., Horvath, L.,
O'Toole, S. (2013). Patterns of DNA mutations
and ALK Rearrangement in Resected Node
Negative Lung Adenocarcinoma. Journal of
Thoracic Oncology, 8(4), 408-414. <a
href="http://dx.doi.org/10.1097/JTO.0b013e3182
83558e">[More Information]</a>
Selinger, C., Rogers, T., Russell, P., O'Toole, S.,
Yip, P., Wright, G., Wainer, Z., Horvath, L.,
Boyer, M., McCaughan, B., et al (2013). Testing
for ALK rearrangement in lung adenocarcinoma:
A multicenter comparison of
immunohistochemistry and fluorescent in situ
hybridization. Modern Pathology, 26(12),
1545-1553. <a
href="http://dx.doi.org/10.1038/modpathol.2013.
87">[More Information]</a>
2012
Kim, G., Mahoney, M., Szydlo, D., Mok, T.,
Marshke, R., Holen, K., Picus, J., Boyer, M.,
Pitot, H., Rubin, J., et al (2012). An international,
multicenter phase II trial of bortezomib in
patients with hepatocellular carcinoma.
Investigational New Drugs, 30(1), 387-394. <a
href="http://dx.doi.org/10.1007/s10637-010-953
2-1">[More Information]</a>
Sundaresan, P., Hruby, G., Hamilton, A., Hong,
A., Boyer, M., Chatfield, M., Thompson, J.
(2012). Definitive Radiotherapy or
Chemoradiotherapy in the Treatment of Merkel
Cell Carcinoma. Clinical Oncology, 24(9),
e131-e136. <a
href="http://dx.doi.org/10.1016/j.clon.2012.04.0
07">[More Information]</a>
Boyer, M., McCaughan, B., Barnes, D., Yip, P.
(2012). Diagnosis and treatment of lung cancer:
A focus on the GPs role. Medicine Today, 13(2),
30-36.
Boyer, M., Horwood, K., Pavlakis, N., de Souza,
P., Millward, M., Stein, B., Johnston, M., Abell,
F., Rischin, D. (2012). Efficacy of erlotinib in
patients with advanced Non-small-cell Lung
Cancer (NSCLC): Analysis of the Australian
subpopulation of the TRUST study. Asia-Pacific
Journal of Clinical Oncology, 8(3), 248-254. <a
href="http://dx.doi.org/10.1111/j.1743-7563.201
2.01540.x">[More Information]</a>
Yeo, W., Chung, H., Chan, S., Wang, L., Lim,
R., Picus, J., Boyer, M., Mo, F., Koh, J., Rha, S.,
et al (2012). Epigenetic Therapy Using
Belinostat for Patients With Unresectable
Hepatocellular Carcinoma: A Multicenter Phase
I/II Study With Biomarker and Pharmacokinetic
Analysis of Tumors From Patients in the Mayo
Phase II Consortium and the Cancer
Therapeutics Research Group. Journal of
Clinical Oncology, 30(27), 3361-3367. <a
href="http://dx.doi.org/10.1200/JCO.2011.41.23
95">[More Information]</a>
Ramalingam, S., Blackhall, F., Krzakowski, M.,
Barrios, C., Park, K., Bover, I., Heo, D., Rosell,
R., Talbot, D., Frank, R., Boyer, M., et al (2012).
Randomized Phase II Study of Dacomitinib
(PF-00299804), an Irreversible Pan-Human
Epidermal Growth Factor Receptor Inhibitor,
Versus Erlotinib in Patients With Advanced
Non-Small-Cell Lung Cancer. Journal of
Clinical Oncology, 30(27), 3337-3344. <a
href="http://dx.doi.org/10.1200/JCO.2011.40.94
33">[More Information]</a>
Dhillon, H., Van Der Ploeg, H., Bell, M., Boyer,
M., Clarke, S., Vardy, J. (2012). The impact of
Publications for Michael Boyer
physical activity on fatigue and quality of life in
lung cancer patients: A randomised controlled
trial protocol. BMC Cancer, 12, 1-9. <a
href="http://dx.doi.org/10.1186/1471-2407-12-5
72">[More Information]</a>
2011
Vansteenkiste, J., Solomon, B., Boyer, M., Wolf,
J., Miller, N., Di Scala, L., Pylvaenaeinen, I.,
Petrovic, K., Dimitrijevic, S., Anrys, B., et al
(2011). Everolimus in Combination with
Pemetrexed in Patients with Advanced
Non-small Cell Lung Cancer Previously Treated
with Chemotherapy: A Phase I Study Using a
Novel, Adaptive Bayesian Dose-Escalation
Model. Journal of Thoracic Oncology, 6(12),
2120-2129. <a
href="http://dx.doi.org/10.1097/JTO.0b013e3182
307ede">[More Information]</a>
Yan, T., Cao, C., Boyer, M., Tin, M., Kennedy,
C., McLean, J., Bannon, P., McCaughan, B.
(2011). Improving survival results after surgical
management of malignant pleural mesothelioma:
an Australian institution experience. Annals of
Thoracic and Cardiovascular Surgery, 17(3),
243-249. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=21697784">[More Information]</a>
Cox, K., Goel, S., O'Connell, R., Boyer, M.,
Beale, P., Simes, R., Stockler, M. (2011).
Randomized cross-over trial comparing inpatient
and outpatient administration of high-dose
cisplatin. Internal Medicine Journal, 41(2),
172-178. <a
href="http://dx.doi.org/10.1111/j.1445-5994.201
0.02201.x">[More Information]</a>
Hirsh, V., Paz-Ares, L., Boyer, M., Rosell, R.,
Middleton, G., Eberhardt, W., Szczesna, A.,
Reiterer, P., Saleh, M., Arrieta, O., et al (2011).
Randomized Phase III Trial of
Paclitaxel/Carboplatin With or Without
PF-3512676 (Toll-Like Receptor 9 Agonist) As
First-Line Treatment for Advanced
Non-Small-Cell Lung Cancer. Journal of
Clinical Oncology, 29(19), 2667-2674. <a
href="http://dx.doi.org/10.1200/JCO.2010.32.89
71">[More Information]</a>
Cooper, W., O'Toole, S., Boyer, M., Horvath, L.,
Mahar, A. (2011). What's new in non-small cell
lung cancer for pathologists: the importance of
accurate subtyping, EGFR mutations and ALK
rearrangements. Pathology, 43(2), 103-115. <a
href="http://dx.doi.org/10.1097/PAT.0b013e328
342629d">[More Information]</a>
2010
Kao, S., McCaughan, B., Muljono, A., Boyer, M.
(2010). A pathological complete response in
malignant pleural mesothelioma after
combination chemotherapy with Carboplatin and
pemetrexed. Journal of Thoracic Oncology, 5(3),
405-406. <a
href="http://dx.doi.org/10.1097/JTO.0b013e3181
c8cb16">[More Information]</a>
Moore, M., Stockler, M., Lim, R., Mok, T.,
Millward, M., Boyer, M. (2010). A phase II
study of fenretinide in patients with hormone
refractory prostate cancer: a trial of the Cancer
Therapeutics Research Group. Cancer
Chemotherapy and Pharmacology, 66(5),
845-850. <a
href="http://dx.doi.org/10.1007/s00280-009-122
8-x">[More Information]</a>
Grimison, P., Stockler, M., Thomson, D., Olver,
I., Harvey, V., Gebski, V., Lewis, C., Levi, J.,
Boyer, M., Gurney, H., Boland, A., Simes, R., et
al (2010). Comparison of Two Standard
Chemotherapy Regimens for Good-Prognosis
Germ Cell Tumors: Updated Analysis of a
Randomized Trial. Journal of the National
Cancer Institute, 102(16), 1253-1262. <a
href="http://dx.doi.org/10.1093/jnci/djq245">[M
ore Information]</a>
Kao, S., Pavlakis, N., Harvie, R., Vardy, J.,
Boyer, M., van Zandwijk, N., Clarke, S. (2010).
High blood neutrophil-to-lymphocyte ratio is an
indicator of poor prognosis in malignant
mesothelioma patients undergoing systemic
therapy. Clinical Cancer Research, 16(23),
5805-5813. <a
href="http://dx.doi.org/10.1158/1078-0432.CCR10-2245">[More Information]</a>
Oh, B., Butow, P., Mullan, B., Clarke, S.,
Tattersall, M., Boyer, M., Beale, P., Vardy, J.,
Pavlakis, N., Larke, L. (2010). Patient-Doctor
Communication: Use of Complementary and
Alternative Medicine by Adult Patients with
Cancer. Journal of the Society for Integrative
Oncology, 8(2), 56-64. <a
href="http://dx.doi.org/10.2310/7200.2009.0028"
>[More Information]</a>
2009
Pezaro, C., Rosenthal, M., Gurney, H., Davis, I.,
Underhill, C., Boyer, M., Kotasek, D., Soloman,
B., Toner, G. (2009). An Open-Label,
Single-Arm Phase Two Trial of Gefitinib in
Patients With Advanced or Metastatic
Castration-Resistant Prostate Cancer. American
Journal of Clinical Oncology, 32(4), 338-341. <a
href="http://dx.doi.org/10.1097/COC.0b013e318
18b946b">[More Information]</a>
Soon, Y., Stockler, M., Askie, L., Boyer, M.
(2009). Duration of Chemotherapy for Advanced
Non-Small-Cell Lung Cancer: A Systematic
Review and Meta-Analysis of Randomized
Trials. Journal of Clinical Oncology, 27(20),
Publications for Michael Boyer
3277-3283. <a
href="http://dx.doi.org/10.1200/JCO.2008.19.45
22">[More Information]</a>
Vardy, J., Dadasovich, R., Beale, P., Boyer, M.,
Clarke, S. (2009). Eligibility of patients with
advanced non-small cell lung cancer for phase III
chemotherapy trials. BMC Cancer, 9, 1-6. <a
href="http://dx.doi.org/10.1186/1471-2407-9-13
0">[More Information]</a>
Yan, T., Boyer, M., Tin, M., Wong, D.,
Kennedy, C., McLean, J., Bannon, P.,
McCaughan, B. (2009). Extrapleural
pneumonectomy for malignant pleural
mesothelioma: outcomes of treatment and
prognostic factors. The Journal of Thoracic and
Cardiovascular Surgery, 138(3), 619-624. <a
href="http://dx.doi.org/10.1016/j.jtcvs.2008.12.0
45">[More Information]</a>
Zhao, L., Lee, B., Brown, D., Molloy, M., Marx,
G., Pavlakis, N., Boyer, M., Stockler, M.,
Kaplan, W., Breit, S., et al (2009). Identification
of candidate biomarkers of therapeutic response
to docetaxel by proteomic profiling. Cancer
Research, 69(19), 7696-7703. <a
href="http://dx.doi.org/10.1158/0008-5472.CAN
-08-4901">[More Information]</a>
Simonella, L., O’Connell, D., Vinod, S.,
Delaney, G., Boyer, M., Esmaili, N., Hensley,
M., Goldsbury, D., Supramaniam, R., Hui, A.,
Armstrong, B. (2009). No improvement in lung
cancer care: The management of lung cancer in
1996 and 2002 in New South Wales. Internal
Medicine Journal, 39, 453-458. <a
href="http://dx.doi.org/10.1111/j.1445-5994.200
8.01788.x">[More Information]</a>
Yan, T., Boyer, M., Tin, M., Sim, J., Kennedy,
C., McLean, J., Bannon, P., McCaughan, B.
(2009). Prognostic features of long-term
survivors after surgical management of
malignant pleural mesothelioma. The Annals of
Thoracic Surgery, 87(5), 1552-1556. <a
href="http://dx.doi.org/10.1016/j.athoracsur.2009
.01.026">[More Information]</a>
Soon, Y., Stockler, M., Boyer, M. (2009). Reply
to A.D. Sasse et al. Journal of Clinical
Oncology, 27(35), e254. <a
href="http://dx.doi.org/10.1200/JCO.2009.25.37
57">[More Information]</a>
Tattersall, M., Dear, R., Jansen, J., Shepherd, H.,
Devine, R., Horvath, L., Boyer, M. (2009).
Second opinions in oncology: the experiences of
patients attending the Sydney Cancer Centre.
Medical Journal of Australia, 191(4), 209-212.
<a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=19705981">[More Information]</a>
2008
Martin, R., Fulham, M., Shannon, K., Hughes,
C., Gao, K., Milross, C., Tin, M., Jackson, M.,
Clifford, A., Boyer, M., O'Brien, C. (2008).
Accuracy of positron emission tomography in the
evaluation of patients treated with
chemoradiotherapy for mucosal head and neck
cancer. Head and Neck, 31(2), 244-250. <a
href="http://dx.doi.org/10.1002/hed.20962">[Mo
re Information]</a>
Vinod, S., O'Connell, D., Simonella, L., Delaney,
G., Boyer, M., Peters, M., Miller, D., Peters, M.,
Supramaniam, R., McCawley, L., Armstrong, B.
(2008). Gaps in optimal care for lung cancer.
Journal of Thoracic Oncology, 3(8), 871-879. <a
href="http://dx.doi.org/10.1097/JTO.0b013e3181
8020c3">[More Information]</a>
Kenny, P., King, M., Viney, R., Boyer, M.,
Pollicino, C., McLean, J., Fulham, M.,
McCaughan, B. (2008). Quality of life and
survival in the 2 years after surgery for
non-small-cell lung cancer. Journal of Clinical
Oncology, 26(2), 233-241. <a
href="http://dx.doi.org/10.1200/JCO.2006.07.72
30">[More Information]</a>
2007
Findlay, M., Storey, D., Gebski, V., Hargreaves,
C., Cullingford, G., Boyer, M., Trotter, J.,
Archer, S., Davidson, A., Johnston, P., Yuen, J.,
Dhillon, H., et al (2007). A pilot study of
preoperative and postoperative chemotherapy in
patients with operable gastric cancer:
Australasian Gastrointestinal Trials Group study
9601. ANZ Journal of Surgery, 77(4), 247-252.
Streit, J., Gao, K., O'Brien, C., Boyer, M.,
Milross, C. (2007). Hn11p primary
chemo-radiotherapy for non-metastatic
squamous cell carcinoma of the head and neck.
ANZ Journal of Surgery, 77, A39.
Yeo, W., Boyer, M., Chung, H., Ong, S., Lim,
R., Zee, B., Ma, B., Lam, K., Mo, F., Ng, E.,
Clarke, S., Beale, P., et al (2007). Irofulven as
first line therapy in recurrent or metastatic gastric
cancer: a phase II multicenter study by the
Cancer Therapeutics Research Group (CTRG).
Cancer Chemotherapy and Pharmacology,
59(3), 295-300. <a
href="http://dx.doi.org/10.1007/s00280-006-027
0-1">[More Information]</a>
Chuah, B., Lim, R., Boyer, M., Ong, A., Wong,
S., Kong, H., Millward, M., Clarke, S., Goh, B.
(2007). Multi-centre phase II trial of
Thalidomide in the treatment of unresectable
hepatocellular carcinoma. Acta Oncologica,
46(2), 234-238. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
Publications for Michael Boyer
&list_uids=17453375">[More Information]</a>
Miller, D., Boyer, M., Supramaniam, R.,
Armstrong, B., Simonella, L., O'Connell, D.,
Vinod, S., McCawley, L., Delaney, G. (2007).
Patterns of lung cancer care in NSW, Australia.
12th World Conference on Lung Cancer, United
Kingdom: Wiley-Blackwell Publishing.
Oates, J., Clark, J., Jane, R., Reeves, N., Gao, K.,
Jackson, M., Boyer, M., O'Brien, C. (2007).
Prospective evaluation of quality of life and
nutrition before and after treatment for
nasopharyngeal carcinoma. Archives Of
Otolaryngology-Head and Neck Surgery, 133(6),
533-540. <a
href="http://dx.doi.org/10.1001/archotol.133.6.5
33">[More Information]</a>
2006
Soo, R., Wang, L., Tham, L., Yong, W., Boyer,
M., Lee, H., Lim, H., Millward, M., Liang, S.,
Beale, P., et al (2006). A multicentre randomised
phase II study of carboplatin in combination with
gemcitabine at standard rate or fixed dose rate
infusion in patients with advanced stage
non-small-cell lung cancer. Annals of Oncology,
17(7), 1128-1133.
Stockler, M., Tattersall, M., Boyer, M., Clarke,
S., Beale, P., Simes, R. (2006). Disarming the
guarded prognosis: predicting survival in newly
referred patients with incurable cancer. British
Journal of Cancer, 94(2), 208-212. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16404420">[More Information]</a>
Hsin, K., Boyer, M., Ducreux, M., Liu, M., Soo,
R., Yeo, W., Williams, K., Johri, A. (2006).
Efficacy of patupilone in advanced local or
metastatic gastric cancer: A phase IIa trial.
Journal of Clinical Oncology, 24(18S), 195
(Abstract 4069)-195.
Abratt, R., Lee, J., Han, J., Tsai, C., Boyer, M.,
Mok, T., Kim, S., Lee, J., Brnabic, A., Reece, W.
(2006). Phase II trial of
gemcitabine-carboplatin-paclitaxel as
neoadjuvant chemotherapy for operable
non-small cell lung cancer. Journal of Thoracic
Oncology, 1(2), 135-140.
response, and quality of life in patients with
advanced hepatocellular carcinoma treated with
long-acting octreotide. British Journal of
Cancer, 95(7), 853-861. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16953241">[More Information]</a>
2005
Clarke, S., Boyer, M., Millward, M., Underhill,
C., Moylan, E., Yip, D., White, S., Childs, A.,
Beale, P., Latz, J., et al (2005). A phase I/II study
of pemetrexed and vinorelbine in patients with
non-small cell lung cancer. Lung Cancer, 49(3),
401-412. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15923057">[More Information]</a>
van Meerbeeck, J., Boyer, M. (2005). Consensus
report: pretreatment minimal staging and
treatment of potentially resectable malignant
pleural mesothelioma. Lung Cancer,
49(Supplement 1), S123-S127. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15950792">[More Information]</a>
Sharma, R., Boyer, M., Clarke, S., Millward, M.
(2005). Gefitinib in advanced non-small cell lung
cancer. Internal Medicine Journal, 35(2), 77. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15705135">[More Information]</a>
Underhill, C., Hui, R., Links, M., Hawson, G.,
Chern, B., Yip, D., Blackwell, T., Crombie, C.,
Boyer, M. (2005). Phase II study of docetaxel
and celecoxib as first or second line therapy in
patients with advanced NSCLC. Lung Cancer,
49(Sup.2), S272-S273.
Joshua, A., Boyer, M., Subramanian, R., Clarke,
S. (2005). Smoking reduction does work:
resulting alterations in the incidence and
histological subtypes of lung cancer in New
South Wales in the last 20 years. Respirology,
10(2), 233-238. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15823191">[More Information]</a>
Charles (nee Slaviero), K., Rivory, L., Stockler,
M., Beale, P., Beith, J., Boyer, M., Clarke, S.
(2006). Predicting the toxicity of weekly
docetaxel in advanced cancer. Clinical
Pharmacokinetics, 45(6), 611-622. <a
href="http://dx.doi.org/10.2165/00003088-20064
5060-00004">[More Information]</a>
Clarke, S., Boyer, M., Stockler, M.,
Venkatawaran, R., Nordman, I., Joshua, A.
(2005). Weekly docetaxel as second line
treatment after mitoxantrone for
androgen-independent prostate cancer (AIPC).
2005 ASCO Annual Meeting, NY, USA:
American Society of Clinical Oncology.
Cebon, J., Hargreaves, C., Stockler, M., Boyer,
M., Nowak, A., Dhillon, H., Gebski, V.,
Dickman, B., Findlay, M., Poon, A., et al (2006).
Somatostatin receptor expression, tumour
Joshua, A., Nordman, I., Venkataswaran, R.,
Clarke, S., Stockler, M., Boyer, M. (2005).
Weekly docetaxel as second line treatment after
mitozantrone for androgen-independent prostate
Publications for Michael Boyer
cancer. Internal Medicine Journal, 35(8),
468-472. <a
href="http://dx.doi.org/10.1111/j.1445-5994.200
5.00883.x">[More Information]</a>
2004
Cox, K., O'Connell, R., Stockler, M., Boyer, M.,
Beale, P., Simes, R. (2004). A randomized
crossover trial of giving high-dose cisplatin with
or without an overnight stay in hospital: Patients'
preferences, quality of life, safety and resource
use. Journal of Clinical Oncology, 22(14S),
547S-547S.
Butow, P., Boyer, M., Tattersall, M., Pendlebury,
S., Jackson, M., Fung, C. (2004). Cancer
Consultation Preparation Package: Changing
Patients But Not Physicians Is Not Enough.
Journal of Clinical Oncology, 22(21),
4401-4409.
Vardy, J., Engelhardt, K., Cox, K., Jacquet, J.,
McDade, A., Boyer, M., Beale, P., Clarke, S.,
Stockler, M., Loneragan, R., Waugh, R., Clarke,
S. (2004). Long-Term Outcome Of
Radiological-Guided Insertion Of Implanted
Central Venous Access Port Devices (Cvapd)
For The Delivery Of Chemotherapy In Cancer
Patients: Institutional Experience And Review
Of The Literature. British Journal of Cancer,
91(6), 1045-1049.
Joshua, A., Stockler, M., Boyer, M. (2004).
Prolonged survival after the diagnosis of
metastatic hepatic epitheliod
haemangioendothelioma. Internal Medicine
Journal, 34(1-2), 70-71.
Zhang, M., Boyer, M., Rivory, L., Hong, A.,
Clarke, S., Stevens, G., Fife, K. (2004).
Radiosensitization Of Vinorelbine And
Gemcitabine In Nci-H460 Non-Small-Cell Lung
Cancer Cells. International Journal of Radiation:
Oncology - Biology - Physics, 58(2), 353-360. <a
href="http://dx.doi.org/10.1016/j.ijrobp.2003.09.
032">[More Information]</a>
Viney, R., Boyer, M., King, M., Kenny, P.,
Pollicino, C., McLean, J., McCaughan, B.,
Fulham, M. (2004). Randomized Controlled
Trial Of The Role Of Positron Emission
Tomography In The Management Of Stage I
And Ii Non-Small-Cell Lung Cancer. Journal of
Clinical Oncology, 22(12), 2357-2362.
2003
Millward, M., Boyer, M., Lehnert, M., Clarke,
S., Rischin, D., Goh, B., Wong, J., McNeil, E.,
Bishop, J. (2003). Docetaxel and carboplatin is
an active regimen in advanced non-small-cell
lung cancer: a phase II study in Caucasian and
Asian patients. Annals of Oncology, 14(3),
449-454.
Abol-Enein, H., Bassi, P., Boyer, M., Coppin, C.,
Cortesi, E., Hall, R., Horwich, A., Malmström,
P., Martinez-Piñeiro, J., Sengelov, L., et al
(2003). Neoadjuvant chemotherapy in invasive
bladder cancer: A systematic review and
meta-analysis. The Lancet, 361(9373),
1927-1934.
Vogelzang, N., Rusthoven, J., Symanowski, J.,
Denham, C., Kaukel, E., Ruffie, P., Gatzemeier,
U., Boyer, M., Emri, S., Manegold, C., et al
(2003). Phase III study of premetrexed in
combination with cisplatin versus cisplatin alone
in patients with malignant pleural mesothelioma.
Journal of Clinical Oncology, 21(14),
2636-2644.
Boyer, M. (2003). Pleural and pericardial
effusions. In Fisch, Bruera (Eds.), Handbook of
Advanced Cancer Care, (pp. 481-487). UK:
Cambridge University Press.
2002
Cullingford, G., Findlay, M., Storey, D., Boyer,
M., Trotter, J., Archer, S., Davidson, A.,
Johnston, P., Gebski, V., Dhillon, H. (2002). A
phase II feasibility study of pre-operative and
post-operative chemotherapy (epirubicin,
cisplatin and 4FU (ECF)) in patients with
advanced but operable gastric cancer: and
Australasian Gastro-Intestinal Trials Group
(AGITG) study (AG9601). 38th Annual Meeting
of ASCO.
Boyer, M., Stockler, M., Rosenthal, M., Eisinger,
D., Goad, J., Webb, D. (2002). Adjuvant
mitoxantrone chemotherapy for men at high risk
of relapse following radical prostatectomy: a
pilot study. UroOncology, 2(1), 15-17.
Boyer, M., Clarke, S. (2002). Current
management of lung cancer. Current
Therapeutics: Australia's journal of disease
management and drug treatment, 43/44(12/1),
49-54.
Cassidy, J., Twelves, C., Cutsem, E., Hoff, P.,
Bajetta, E., Boyer, M., Bugat, R., Burger, U.,
Garin, A., Graeven, U., et al (2002). First-line
oral capecitabine therapy in metastatic colorectal
cancer: a favourable safety profile compared
with intravenous 5-fluorouracil/leucovorin.
Annals of Oncology, 13, 566-575.
Boyer, M., Rivory, L., Clarke, S. (2002).
Pemetrexed: single-agent and combination phase
1 study overview. Seminars in Oncology, 29(6 Supplement 18), 18-23.
Clarke, S., Abratt, R., Goedhals, L., Boyer, M.,
Millward, M., Ackland, S. (2002). Phase II trial
of pemetrexed disodium (ALIMTA[R],
LY231514) in chemotherapy-naive patients with
advanced non-small-cell lung cancer. Annals of
Oncology, 13(5), 737-741.
Publications for Michael Boyer
Horvath, L., McCaughan, B., Stockler, M.,
Boyer, M. (2002). Resection of residual
pulmonary masses after chemotherapy in patients
with metastatic non-seminomatous germ cell
tumours. Internal Medicine Journal, 32(3),
79-83.
2001
Toner, G., Stockler, M., Boyer, M., Jones, M.,
Thomson, D., Harvey, V., Olver, I., Dhillon, H.,
McMullen, A., Gebski, V., Levi, J., Simes, R.
(2001). Comparison of two standard
chemotherapy regimens for good-prognosis
germ-cell tumours: a randomised trial. The
Lancet, 357(9528), 739-745.
Rivory, L., Clarke, S., Boyer, M., Bishop, J.
(2001). Highly sensitive analysis of the antifolate
pemetrexed sodium, a new cancer agent, in
human plasma and urine by high-performance
liquid chromatography. Journal of
Chromatography. B, Analytical Technologies in
the Biomedical and Life Sciences, 765, 135-140.
2000
Rischin, D., Boyer, M., Smith, J., Millward, M.,
Michael, M., Bishop, J., Zalcberg, J., Davison, J.,
Emmett, E., McClure, B. (2000). A phase I trial
of docetaxel and gemcitabine in patients with
advanced cancer. Annals of Oncology, 11,
421-426.
Rischin, D., Smith, J., Millward, M., Lewis, C.,
Richardson, G., Boyer, M., Toner, G., Gurney,
H., McKendrick, J. (2000). A phase II trial of
paclitaxel and epirubicin in advanced breast
cancer. British Journal of Cancer, 83(4),
438-442.
Dowsett, S., Saul, J., Butow, P., Dunn, S., Boyer,
M., Findlow, R., Dunsmore, J. (2000).
Communication styles in the cancer consultation:
preferences for a patient-centred approach.
Psycho-Oncology, 9, 147-156.
Rivory, L., Charles (nee Slaviero), K., Seale, J.,
Hoskins, J., Boyer, M., Beale, P., Millward, M.,
Bishop, J., Clarke, S. (2000). Optimizing the
erythromycin breath test for use in cancer
patients. Clinical Cancer Research, 6,
3480-3485.
Klasterksy, J., Paesmans, M., Rubenstein, E.,
Boyer, M., Elting, L., Feld, R., Gallagher, J.,
Herrstedt, J., Rapoport, B., et, A. (2000). The
multinational association for supportive care in
cancer risk index: a multinational scoring system
for identifying low-risk febrile neutropenic
cancer patients. Journal of Clinical Oncology,
18, 3038-3051.
von Pawel, J., von Roemeling, R., Gatzemeier,
U., Boyer, M., Elisson, L., Clark, P., Talbot, D.,
Rey, A., Butler, T., Hirsh, V., et al (2000).
Tirapazamine plus cisplatin versus cisplatin in
advanced non-small-cell lung cancer: a report of
the international CATAPULT I study group.
Journal of Clinical Oncology, 18, 1351-1359.